文献速递妇科

局部外用咪喹莫特治疗残留或复发性宫颈上皮内瘤变病变(TOPIC-2):一项随机对照试验

Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trial.
PubMed 文献 · BJOG · 2024-03-31

这项在荷兰两家医院开展的随机对照非劣效性试验纳入35例残留或复发性宫颈上皮内瘤变(rrCIN)女性,比较5%咪喹莫特乳膏阴道内用药与LLETZ手术。结果显示咪喹莫特组细胞学转正常率为33%(6/18),LLETZ组为100%(16/16),HPV清除率分别为22%(4/18)和88%(14/16),差异均有统计学意义(P<0.001)。因咪喹莫特治疗无效被证实,试验提前终止。

要点

  • 咪喹莫特组细胞学转正常率33%(6/18)vs LLETZ组100%(16/16),P<0.001。
  • 咪喹莫特组高危HPV清除率22%(4/18)vs LLETZ组88%(14/16),P<0.001。
  • 咪喹莫特有大量副作用,且多数患者用后仍需追加手术治疗。

核心结论

  • 这是首个随机对照试验,显示在rrCIN女性中,局部外用咪喹莫特在细胞学转正常和高危HPV清除方面的成功率显著低于LLETZ。
  • 咪喹莫特有大量副作用,且使用咪喹莫特后多数rrCIN女性仍需追加手术治疗。

研究设计与样本

  • 随机对照非劣效性试验,在荷兰一家学术医院和一家地区医院开展。
  • 2016年5月至2021年5月共纳入35例残留或复发性宫颈上皮内瘤变(rrCIN)女性。
  • 受试者随机接受5%咪喹莫特乳膏(12.5 mg)阴道内用药(每周三次,持续16周)或LLETZ手术(标准治疗)。
  • 主要结局为开始治疗后6个月细胞学转正常。
  • 次要结局为两组高危人乳头瘤病毒(hr-HPV)清除及咪喹莫特组降至≤CIN1,并监测副作用。

主要发现

  • 治疗成功率咪喹莫特组为33%(6/18),LLETZ组为100%(16/16),P<0.001。
  • HPV清除率咪喹莫特组为22%(4/18),LLETZ组为88%(14/16),P<0.001。
  • 随机分组35例女性后,咪喹莫特治疗无效被证实,试验提前终止。
  • 随访期间,3例患者未接受额外治疗,其余所有患者接受了LLETZ、锥切或子宫切除术。
  • LLETZ组在2年随访期间无患者接受额外治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy of imiquimod in women with residual or recurrent cervical intraepithelial neoplasia (rrCIN), compared with large loop excision of the transformation zone (LLETZ). DESIGN: Randomised controlled non-inferiority trial. SETTING: One academic and one regional hospital in the Netherlands. POPULATION: Thirty-five women with rrCIN were included in the study between May 2016 and May 2021. METHODS: Women were randomised to receive treatment with 5% imiquimod cream (12.5 mg) intravaginally (three times a week for a duration of 16 weeks) or a LLETZ procedure (standard treatment). MAIN OUTCOME MEASURES: The primary outcome was reduction to normal cytology at 6 months after starting treatment. Secondary outcomes were clearance of high-risk human papilloma virus (hr-HPV) in both groups and reduction to ≤CIN1 in the imiquimod group. Side effects were monitored. RESULTS: Treatment success was 33% (6/18) in the imiquimod group versus 100% (16/16) in the LLETZ group (P < 0.001), whereas HPV clearance was 22% (4/18) in the imiquimod group versus 88% (14/16) in the LLETZ group (P < 0.001). After the randomisation of 35 women, the futility of treatment with imiquimod was proven and the trial was prematurely finished. In the follow-up period, three patients remained without additional treatment, whereas all other patients underwent LLETZ, conisation or hysterectomy. In the LLETZ group none of the patients received additional treatment during 2 years of follow-up. CONCLUSIONS: This is the first randomised controlled trial to show that topical imiquimod has a significantly lower success rate in terms of reduction to normal cytology and hr-HPV clearance, compared with LLETZ, in women with rrCIN. Additionally, imiquimod has numerous side effects and after using imiquimod most women with rrCIN still required additional surgical treatment.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. van de Sande AJM, van Baars R, Koeneman MM, et al. Topical imiquimod treatment of residual or recurrent cervical intraepithelial neoplasia lesions (TOPIC-2): A randomised controlled trial. BJOG. 2024. PMID: 38556619. doi:10.1111/1471-0528.17808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。